Caroline Palomeque
Stock Analyst at Maxim Group
(1.28)
# 3,590
Out of 5,064 analysts
10
Total ratings
44.44%
Success rate
-2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $1.68 | +376.19% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $34.31 | +71.96% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $212.02 | -27.37% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $70.34 | -17.54% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $210.49 | -21.14% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $18.00 | +116.67% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $11.80 | +416.95% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $3.26 | +1,126.99% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $1.68
Upside: +376.19%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $34.31
Upside: +71.96%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $212.02
Upside: -27.37%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $70.34
Upside: -17.54%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $210.49
Upside: -21.14%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $18.00
Upside: +116.67%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $11.80
Upside: +416.95%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $3.26
Upside: +1,126.99%